Objective. Giant cell arteritis (GCA) and the use of glucocorticoids have both been associated with increased risk of venous thromboembolism (VTE). However, the possibility of confounding by indication has not been investigated. We undertook this study to examine the temporal risk of VTE in GCA patients before and after GCA diagnosis, accounting for confounders including glucocorticoid treatment.
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Objective. Giant cell arteritis (GCA) and the use of glucocorticoids have both been associated with increased risk of venous thromboembolism (VTE). However, the possibility of confounding by indication has not been investigated. We undertook this study to examine the temporal risk of VTE in GCA patients before and after GCA diagnosis, accounting for confounders including glucocorticoid treatment.
Methods. We conducted a matched cohort study using an electronic medical record database representative of the UK population . We calculated age-, sex-, and entry time-matched and multivariate relative risks (RRs) of VTE, comparing 6,441 patients with new-onset GCA (defined by corresponding diagnosis codes and prescribed glucocorticoid treatment) to 63,985 controls before and after GCA diagnosis. Analysis before GCA diagnosis was stratified by oral glucocorticoid use to account for confounding.
Results. There were 27 incident VTE events during the 12 months preceding GCA diagnosis and 195 afterward. Compared to controls, during the 12, 9, 6, and 3 months preceding GCA diagnosis, the age-, sex-, and entry time-matched RRs for VTE among patients with imminent GCA not treated with glucocorticoids were 1.8, 2.2, 2.4, and 3.6, respectively. In the first 3, 6, 12, 24, 48, and 96 months after GCA diagnosis, the corresponding RRs were 9.9, 7.7, 5.9, 4.4, 3.3, and 2.4. Multivariate analyses including several common VTE risk factors showed similar trends.
Conclusion. The risk of VTE increases shortly before GCA diagnosis, peaks at the time of diagnosis, and then progressively declines thereafter. This risk is apparent in patients with imminent GCA unexposed to oral glucocorticoids, suggesting a role for inflammationassociated thrombosis that is independent of glucocorticoid use.
Giant cell arteritis (GCA) is the most common type of primary vasculitis in adults (1) . The disease causes inflammation in large-and medium-sized arteries and is characterized by a relapsing course (1) . No curative treatment currently exists for GCA, and no medication except glucocorticoids has been convincingly shown to be effective in suppressing disease activity. Most GCA patients require high doses of glucocorticoids to achieve remission and prolonged glucocorticoid tapers to prevent relapses (1) .
The pathways of inflammation are associated with those of hemostasis (2) . Immune-mediated thrombosis (immunothrombosis) is increasingly recognized as an independent mechanism that participates in the recognition of pathogens and damaged cells and inhibits microbial dissemination and survival (2-4). Thus, dysregulation of the factors that control immunothrombosis may lead to inappropriate blood clotting. In fact, cumulative evidence has demonstrated an increased incidence of deep vein thrombosis (DVT) and pulmonary embolism in various types of inflammatory disorders, such as rheumatoid arthritis, lupus, and several forms of vasculitis (5) (6) (7) (8) (9) (10) (11) (12) prothrombotic phenotype (8) . Under conditions in which no underlying venous angiitis is evident (e.g., rheumatoid arthritis), it is speculated that systemic inflammation not only causes widespread endothelial dysfunction, but also alters the balance between the coagulation and fibrinolytic systems, leading to generalized thrombophilic diathesis (13) (14) (15) (16) (17) .
Inflammation in GCA is confined to the arterial side of the circulation (18) . Therefore, the risk of venous thromboembolism (VTE) has not been explored in this disease until recently (19, 20) . However, available data are limited, and key aspects of the putative GCA-associated thrombophilia, such as the risk of VTE immediately before disease diagnosis-when inflammation is expected to surge-remain unknown. Moreover, glucocorticoids, which are universally used to treat GCA-related inflammation, have been ascribed procoagulant properties (21, 22) . Thus, the possibility of confounding by indication should be examined in order to define the risk of VTE in GCA more accurately.
We evaluated the risk of VTE in a large cohort of GCA patients before and after GCA diagnosis, accounting for a comprehensive group of prothrombotic risk factors. In addition, we investigated the potential confounding effect of glucocorticoids.
PATIENTS AND METHODS
Data source. The Health Improvement Network (THIN) is a computerized medical database from general practices in the UK (23) . Data on ;10.2 million patients from 580 general practices are recorded systematically by general practitioners. Because the National Health Service in the UK requires every individual to be registered with a general practitioner regardless of health status (24) , THIN is representative of the general UK population. The database information includes demographics, physician-recorded diagnoses, and additional health data including body mass index (BMI) and smoking status. The Read classification is used to code specific diagnoses (25, 26) . A dictionary based on the Multilex classification is used to code drug prescriptions (Multilex FDB [First Databank] www.fdbhealth.com/ solutions/multilex). The THIN database has been successfully used for research in various medical areas (27) (28) (29) (30) . This study was exempt from institutional review board approval because all data were de-identified beforehand.
Study design and cohort definitions. The study population included individuals age $50 years who had at least 1 year of active enrollment with their general practice from January 1990 through December 2013. We conducted a matched cohort study to examine the incidence and relative risk (RR) of VTE (pulmonary embolism and/or DVT) in patients with new-onset GCA compared with that in up to 10 individuals without GCA matched by age, sex, and date of study entry. Participants entered the cohort 12 months before the date of GCA diagnosis (or on the matched index date for controls) and were followed up until they developed pulmonary embolism or DVT, died, or left the THIN database, or until follow-up ended, whichever came first. Participants with a history of pulmonary embolism or DVT before the date of GCA diagnosis (or the corresponding matched date for controls) were excluded from the analysis of VTE after GCA diagnosis. We refer to the 12 months preceding GCA diagnosis as the imminent GCA period and to the patients who were eventually diagnosed as having GCA as patients with imminent GCA.
Definition of incident GCA. Patients with GCA were defined as those with a diagnostic code of GCA, temporal arteritis, or Horton's disease and who received and used glucocorticoids (30) . Glucocorticoid use was defined as receiving 2 prescriptions for oral glucocorticoids, the first within 6 months of the date of GCA diagnosis and the second within 6 months of the first prescription (30) . This definition of GCA has been shown to have a positive predictive value of 91% in the General Practice Research Database (GPRD), 60% of whose patients overlap with those in THIN (31). We excluded individuals age ,50 years because GCA is exceedingly rare before the sixth decade of life (1).
Outcome definitions. A patient was considered to have developed the outcome of interest when he or she had a recorded diagnosis of pulmonary embolism or DVT and received anticoagulant therapy (32) . In addition, under the assumption that VTE is potentially fatal and therefore some patients might have died before receiving anticoagulation, we also considered patients with a recorded code of pulmonary embolism or DVT in the absence of documented anticoagulant therapy to have had pulmonary embolism or DVT if there was a fatal outcome within 1 month of the VTE diagnosis (32) . Patients were censored upon developing the first outcome of interest (DVT, pulmonary embolism, or both simultaneously).
Covariate assessment. Demographics, smoking status, BMI, and comorbid medical conditions were recorded prior to the start of cohort follow-up. BMI was classified as a 4-level categorical variable (,25, 25-29.9, 30-34.9, or $35 kg/m 2 ). The comorbidities examined were polymyalgia rheumatica (PMR), hypertension, congestive heart failure, myocardial infarction, stroke, atrial fibrillation, peripheral artery disease, chronic obstructive pulmonary disease, diabetes mellitus, chronic kidney disease, varicose veins, inflammatory bowel disease, and cancer. These were all treated as dichotomous variables. The use of aspirin and the occurrence of any trauma, fracture, hospitalization, or surgery were also recorded prior to the start of cohort followup (5). Use of glucocorticoids among patients with imminent GCA and among controls was defined as receiving at least 1 prescription for oral glucocorticoids.
Statistical analysis. We compared the baseline characteristics of patients with GCA to those of the reference participants by use of Wilcoxon's rank sum test for continuous variables and chi-square test for categorical variables. First, to confirm the increased risk of VTE among patients with incident GCA (after diagnosis), we computed the number of person-years of followup for each individual from the time of diagnosis (GCA group) or corresponding matched date (comparison group) to the end of follow-up. We identified incident cases of pulmonary embolism and DVT during follow-up and estimated the incidence rate, both individually and in combination (i.e., pulmonary embolism, DVT, and pulmonary embolism or DVT [VTE] ). The associations between GCA and VTE were then expressed as incidence rate ratios. We used Cox proportional hazards regression models to determine the RRs after stratifying by the matched variables (i.e., age, sex, and calendar year of study entry). We imputed missing values for BMI and smoking using a sequential regression approach (i.e., IVEware for SAS; Institute for Social Research, University of Michigan) assuming that BMI and smoking were missing at random and conditioning on all covariates included in the analysis (33) . In addition, we performed further multivariate analyses controlling for differences in BMI, smoking, the presence of comorbidities, aspirin use, and the occurrence of prior trauma, fracture, surgery, and hospitalization. To determine whether the RR of VTE followed a specific time trend after the diagnosis of GCA, we estimated RRs within 3, 6, 12, 24, 48, and 96 months, which avoids the built-in selection bias associated with RRs for discrete consecutive time intervals (34) .
We performed 3 sensitivity analyses. First, we estimated the cumulative incidence of the outcome events accounting for the competing risk of death (35) . Second, we used a more stringent definition of GCA limited to patients with the disease and receiving $10 prescriptions for glucocorticoids. Third, we conducted a multivariate analysis after excluding individuals with missing information on BMI, smoking, and other covariates.
In order to evaluate the trend of VTE risk before the diagnosis of GCA, we compared incidence rates of VTE during the 12, 9, 6, and 3 months preceding the date of GCA diagnosis between patients with imminent GCA and their age-, sex-, and entry time-matched controls. In addition, to examine the VTE risk trend among those with imminent GCA, independently of potential confounding from glucocorticoids (21, 22) , we performed analyses stratified by oral glucocorticoid use. The underlying rationale was that subjects with imminent GCA might have had subclinical or clinically manifested disease for some time before their GCA diagnosis (with many of them not being exposed to glucocorticoid treatment, unlike after GCA diagnosis). This allowed us to examine the effect on VTE of imminent GCA versus the absence of GCA, independent of glucocorticoid use. Our cohort analyses of patients with imminent GCA were otherwise analogous to those after GCA diagnosis as described above.
For all RRs, we calculated 95% confidence intervals (95% CIs). The cutoff for statistical significance was 0.05, and all P values were 2-sided. All statistical analyses were performed using SAS software, version 9.3 (SAS Institute).
RESULTS
Baseline characteristics of patients with incident GCA. We identified 6,414 patients with new-onset GCA (mean age 73 years, 70% women) and 63,985 matched controls. Subjects were followed up for a median of 5.2 person-years. Table 1 summarizes the baseline characteristics of the patients with GCA and the controls. Compared with controls, patients with GCA tended to be prior and current smokers and to have a higher prevalence of cardiovascular disease. In addition, more patients with GCA tended to use aspirin and had undergone surgery and hospitalization during the preceding year. There were no apparent differences between groups with respect to BMI or the prevalence of fracture, trauma, or cancer. Risk of VTE in imminent GCA. There were 6,441 patients with imminent GCA and 64,259 age-, sex-, and entry time-matched individuals. During the 12 months preceding the date of GCA diagnosis, there were 27 incident VTE events in the imminent GCA group and 150 incident VTE events in the control group (Table 2) . Among patients with imminent GCA, the incidence rate of VTE was 4.2 cases per 1,000 person-years, while the corresponding incidence rate in the comparison group was 2.3 cases per 1,000 person-years. Compared with the control group, the multivariate-adjusted RR for VTE in the imminent GCA group was 1.70 (95% CI 1.11-2.59) ( Table 2) .
In the year preceding the GCA diagnosis, 16% of patients with imminent GCA and 2% of controls were diagnosed as having PMR. Compared to patients with imminent GCA without PMR, patients with imminent GCA and PMR had RRs for DVT, pulmonary embolism, and VTE of 1.13 (95% CI 0.68-1.90), 1.38 (95% CI 0.85-2.24), and 1.24 (95% CI 0.85-1.80), respectively.
Trends of VTE risk in patients with imminent GCA not exposed to glucocorticoids. There were 3,480 patients with imminent GCA (54.0%) and 60,654 matched controls (94.4%) who did not receive glucocorticoids (Table 3) . Among these subjects, 14 patients with imminent GCA Table 3) . Risk of VTE in GCA. During the follow-up period after GCA diagnosis, 1,220 new VTE events occurred (195 in the GCA group and 1,025 in the comparison group). The cumulative incidence of DVT and pulmonary embolism was significantly higher among patients with GCA ( Figure 1 ). In the GCA group, the incidence rate of VTE was 5.9 cases per 1,000 person-years, while the corresponding incidence rate in the comparison group was 2.9 cases per 1,000 personyears (Table 2) . Compared with subjects without GCA, the age-, sex-, and entry time-matched RR for VTE in those with GCA was 2.15 (95% CI 1.83-2.52). After further adjustment for other risk factors associated with VTE, the corresponding RR was 2.06 (95% CI 1.75-2.44) ( Table 2) .
Trends of VTE risk in GCA according to disease duration. The RR of VTE in patients with GCA compared to patients without GCA was highest soon after the diagnosis of GCA. During the first 3, 6, 12, 24, 48, and 96 months of follow-up, the age-, sex-, and entry timematched RRs for VTE were 9.92 (95% CI 6. Table 4) .
Sensitivity analyses. We performed 3 sensitivity analyses to evaluate the robustness of our results (Table 5) . First, our approach accounting for the competing risk of death remained significant with similar results. Second, among the 6,414 patients with GCA, our sensitivity analysis restricted to 3,130 patients who had a GCA diagnosis as well as $10 prescriptions of glucocorticoids remained similarly significant (Table 5 ). Finally, after we excluded individuals with missing data on BMI, smoking, and other covariates, the results did not change significantly (Table 5) .
DISCUSSION
In this large general population cohort, we demonstrated that GCA was strongly associated with an increased risk of VTE. This risk, which was independent of other predisposing factors also known to be linked to hypercoagulable states (36), followed a consistent and compelling temporal pattern. It increased shortly before GCA diagnosis, peaked in the early phase of the disease (;10-fold increase within 3 months of GCA diagnosis), and progressively declined over time thereafter. In addition, we were able to evaluate the risk of VTE among those with imminent GCA who were not exposed to oral glucocorticoids to isolate the impact of GCA pathophysiology (e.g., inflammation) from the purported prothrombotic effects of glucocorticoid treatment (21, 22) . We found an increased risk of VTE as high as 4.1 times among patients with imminent Figure 1 . Cumulative incidence of pulmonary embolism (PE), deep vein thrombosis (DVT), and venous thromboembolism (VTE; pulmonary embolism and/or DVT) among patients with giant cell arteritis (GCA). Cumulative incidence was estimated adjusting for all-cause death as a competing risk.
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GCA who were not exposed to glucocorticoids. Overall, these data support the hypothesis that GCA is an independent risk factor for VTE. Because inflammation in GCA spares the venous circulation (18) , our finding that patients are at greatest risk of VTE in the period surrounding GCA diagnosis (when inflammation is at its highest level), and the demonstration that this risk is not associated with the use of glucocorticoids, suggest that immunothrombosis (2) could play a pathogenic role. In this regard, prior research has demonstrated that the proinflammatory cytokines interleukin-1 (IL-1), IL-6, and tumor necrosis factor a, all of which are up-regulated in patients with GCA (37, 38) , not only may induce endothelial cells, leukocytes, and platelets to acquire prothrombotic phenotypes (13, 39) , but also may regulate components of the coagulation and fibrinolytic systems toward a thrombophilic state (2, 10, 39, 40) .
Our findings after GCA diagnosis are consistent with those of a recent Canadian cohort study derived from population-based administrative data that showed RRs for pulmonary embolism and DVT of 2.7 and 2.5, respectively, in patients with GCA (19) . Although the Canadian study did not account for lifestyle-related factors such as smoking and BMI (both of which are known predisposing factors for VTE), its results were consistent with ours, which have been adjusted for those factors, suggesting that they tend not to confound the association of interest. Furthermore, similar to our results, the incidence of VTE in GCA patients in the Canadian study was highest in the first year following GCA diagnosis. Collectively, these studies provide strong evidence for the increased risk of VTE in GCA, particularly in the first months after diagnosis.
In the last few years, an increased incidence of VTE has been recognized in several other inflammatory pathologies including vasculitides, inflammatory arthritis, and connective tissue diseases (5, 9) . The thrombotic diathesis in these disorders has consistently been demonstrated to be higher during times of active disease (e.g., new-onset or relapsed disease) (11, 19, 41, 42) . However, study designs and methodologies used for the analysis of the problem of VTE in rheumatic diseases have been diverse. In addition, significant differences exist in terms of the baseline characteristics of the patient populations studied (e.g., age, status of disease activity, and comorbidities). All of these factors make direct comparisons among studies challenging. Yet, the risk of VTE might be higher for patients with antineutrophil cytoplasmic antibody-associated vasculitis, inflammatory myopathies, lupus, and scleroderma than for patients with GCA, rheumatoid arthritis, and Sj€ ogren's syndrome (9) (10) (11) (12) 19, 20, (41) (42) (43) (44) (45) (46) (47) .
Our research has several strengths. We were able to study a large group of GCA patients and appropriate controls in a general population setting. Our cohort of .6,000 GCA patients is larger than the ones previously studied (19, 30) . This sample size provided sufficient statistical power to analyze relevant subgroups and estimate the risk for different intervals of the follow-up. Moreover, we restricted disease ascertainment to patients with incident GCA to capture more effectively the entire span of the natural history of the disease and its temporal association with the outcome of interest. In addition, this study is the first to examine the risk of VTE immediately before GCA diagnosis and to account for the potential confounding effect of glucocorticoids. To our knowledge, the possibility of "confounding by indication" has not been addressed in prior studies that examined the risk of VTE in inflammatory disorders.
Our study also has potential limitations. Uncertainty regarding diagnostic accuracy is a concern in studies that identify cases from administrative databases. However, THIN is derived from electronic medical records used for patient care. Thus, the overall accuracy of this database is expected to be high, as reflected in multiple validation studies (48) (49) (50) , including those for VTE (30, 32, 46) . Our operational definition of GCA did not require temporal artery biopsies because biopsy data were not universally available in THIN. Nevertheless, we believe that our definition of GCA effectively captured the GCA patients in the general population, as reflected by the positive predictive value of 91% in the GPRD (31) . Furthermore, a more rigorous definition of GCA that required at least 10 prescriptions for glucocorticoids (reflecting the usual GCA care that entails no less than 6-12 months of prednisone therapy) yielded comparable results. In summary, this population-based study demonstrates that the risk of VTE in GCA patients increases sharply before GCA diagnosis, peaks at the time of diagnosis, and then progressively declines thereafter. This risk is apparent in patients with imminent GCA unexposed to oral glucocorticoids, suggesting a role for inflammationassociated thrombosis independent of glucocorticoid use. Adequate monitoring for VTE is recommended in patients with GCA for early recognition of this potentially serious complication.
